Xometry stock slides about 3.5% in year-end trade; what XMTR investors are watching next
31 December 2025
1 min read

Xometry stock slides about 3.5% in year-end trade; what XMTR investors are watching next

NEW YORK, December 31, 2025, 11:38 ET — Regular session

  • Xometry shares fell about 3.5% in midday trading, outpacing broader market declines.
  • The move came with no fresh company filings or announcements on the SEC’s EDGAR feed.
  • Traders pointed to holiday-thin liquidity and positioning into year-end.

Shares of Xometry Inc fell about 3.5% to $60.94 in midday trading on Wednesday, after closing at $63.14 in the prior session. The Nasdaq-listed stock traded as high as $63.94 and as low as $60.58.

The drop outpaced a modest retreat in U.S. equities on the final trading day of 2025, with broad indexes edging lower in thin holiday liquidity ahead of markets’ New Year’s Day closure. 1

Year-end repositioning has been a focus for investors as 2026 approaches. “It’s just a healthy rebalancing of allocations,” Mark Hackett, chief market strategist at Nationwide, told Reuters in a note on late-December trading. 2

Xometry’s slide came without an obvious single-stock catalyst. An SEC listing of company filings showed Xometry’s most recent quarterly report and earnings-related 8-K were filed on Nov. 4, with no newer company reports posted since then. 3

Xometry operates an online marketplace that connects businesses needing custom-manufactured parts with a network of suppliers, tying its activity to swings in industrial demand and corporate spending. 4

That backdrop has been mixed. The Chicago PMI, a regional gauge of business conditions, rose to 43.5 in December from 36.3 in November, data showed; readings below 50 indicate contraction. 5

The broader industrial complex was only slightly weaker on the day. The Industrial Select Sector SPDR Fund was down about 0.3%, while several manufacturing-adjacent names were also under pressure, including Proto Labs and Stratasys.

Xometry’s pullback also followed a choppy stretch for the stock into year-end. Data from recent sessions showed XMTR trading between roughly $58.5 and $64.9 since mid-December, a range traders often use to mark near-term support and resistance. 6

Investors’ next fundamental checkpoint remains fourth-quarter results, where attention typically centers on revenue growth and profitability measures. In its latest earnings materials, Xometry forecast fourth-quarter revenue of $182 million to $184 million and adjusted EBITDA of $6 million to $7 million; adjusted EBITDA is a profit metric that strips out items such as interest, taxes and depreciation to show operating performance more clearly. 7

Xometry has not posted a next earnings date on Nasdaq’s earnings page, leaving investors to watch for a formal scheduling update from the company. 8

Into 2026, traders are also watching whether improving regional activity data translates into better order flow for manufacturing platforms, and whether year-end positioning reverses once liquidity normalizes after the holidays.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
MIAX slides as year-end trading thins — what traders are watching next
Previous Story

MIAX slides as year-end trading thins — what traders are watching next

Amazon stock slips in year-end trade as Evercore flags AMZN for 2026—what’s next
Next Story

Amazon stock slips in year-end trade as Evercore flags AMZN for 2026—what’s next

Go toTop